ArticleNature communications2023
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 19 citations in OpenAlex.
- Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.British journal of cancer · 2026Review
- PAX3::FOXO1-Targeting PROTAC Induces Myogenic Differentiation of Fusion-Positive Rhabdomyosarcoma Cells.Cancers · 2026Article
- Multi-omics analyses identify EZH2 as a central driver in rhabdomyosarcoma radioresistance and highlight Tazemetostat as an effective radiosensitizer in vitro and in vivo.Cell death & disease · 2026Article
- Single-Cell RNA Analysis of Murine Osteosarcoma Uncovers Skp2 Function in Metastasis, Genomic Instability, and Immune Activation and Reveals Additional Target Pathways.Cancer research communications · 2026Article
- SIRT1 induces FOXO1/autophagy/NCOA4-induced ferroptosis and accelerates the progression of cerebral infarction by inhibiting the E2F1/NOTCH-1/YAP signaling pathway.Scientific reports · 2026Article
- Review
- BMSC-derived exosomes facilitate osteogenesis and ameliorate ageing-related bone loss through restoring Th17/Treg homeostasis via the miR-21/Skp2/FoxO1 axis.Stem cell research & therapy · 2026Article
- From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatment.Frontiers in cell and developmental biology · 2026Review
- Neddylation inhibition induces DNA double-strand breaks, hampering tumor growth in vivo, and promotes radiosensitivity in PAX3-FOXO1 rhabdomyosarcoma.Cell death discovery · 2025Article
- UBE2S inhibits colorectal cancer proliferation by regulating the PI3K/AKT and MAPK/ERK pathways via TRAF6.Scientific reports · 2025Article
- FOXP2 suppresses gastric cancer progression by transcriptionally repressing FBXW2 via WASL degradation.Cell death discovery · 2025Article
- RUNX2 inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and dismantles oncogenic gene programs in fusion-positive rhabdomyosarcoma.bioRxiv : the preprint server for biology · 2025Article
- Trastuzumab Decreases the Expression of G1/S Regulators and Syndecan-4 Proteoglycan in Human Rhabdomyosarcoma.International journal of molecular sciences · 2025Article
- Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Comparative analysis of miRNA-mRNA interaction prediction tools based on experimental head and neck cancer data.Einstein (Sao Paulo, Brazil) · 2025Article
- p57International journal of molecular sciences · 2024Article
- HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks.Cell death discovery · 2024Article
- Myogenesis gone awry: the role of developmental pathways in rhabdomyosarcoma.Frontiers in cell and developmental biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 15 institutions in 4 countries.
Silvia Pomella *Department of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.
Matteo Cassandri *Department of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.
Lucrezia D'ArchivioDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.
Antonella PorrazzoDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.
Cristina CossettiDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.
Doris PhelpsGreehey Children's Cancer Research Institute (GCCRI), UT Health Science Center, San Antonio, TX, USA.
Clara PerroneDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.
Michele PezzellaDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.ORCID 0000-0003-0088-7695
Antonella CardinaleDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.
Marco WachtelDepartment of Oncology and Children's Research Center, University Children's Hospital, Zurich, Switzerland.ORCID 0000-0002-6077-3692
Sara AloisiDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA.
David MilewskiOncogenomics Section, Genetics Branch, National Cancer Institute, NIH,, Bethesda, MD, USA.ORCID 0000-0002-9778-8548
Marta CollettiDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.
Prethish SreenivasGreehey Children's Cancer Research Institute (GCCRI), UT Health Science Center, San Antonio, TX, USA.ORCID 0000-0002-1260-4464
Zoë S WaltersSarcoma Molecular Pathology, Divisions of Molecular Pathology, The Institute of Cancer Research, London, UK.
Giovanni BarillariDepartment of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy.
Angela Di GiannataleDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.
Giuseppe Maria MilanoDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.ORCID 0000-0002-0250-6043
Cristiano De StefanisHistology-Core Facility, Bambino Gesu' Children's Hospital, IRCCS, Rome, Italy.
Rita AlaggioDepartment of Pathology Unit, Department of Laboratories, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Sonia Rodriguez-RodriguezDepartment of Stem Cell and Regenerative Medicine, City of Hope National Medical Center, Duarte, CA, USA.ORCID 0009-0008-5474-8598
Nadia CarlessoDepartment of Stem Cell and Regenerative Medicine, City of Hope National Medical Center, Duarte, CA, USA.ORCID 0000-0002-5131-9885
Christopher R VakocCold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.ORCID 0000-0002-1158-7180
Enrico VelardiDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.
Beat W SchaferDepartment of Oncology and Children's Research Center, University Children's Hospital, Zurich, Switzerland.ORCID 0000-0001-5988-2915
Ernesto GuccioneCenter for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-7764-5307
Susanne A GatzInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, West Midlands, UK.ORCID 0000-0002-6438-9778
Ajla WastiChildren and Young People's Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK.
Marielle YoheLaboratory of Cell and Developmental Signaling, National Cancer Institute, NIH, Frederick, MD, USA.
Myron IgnatiusGreehey Children's Cancer Research Institute (GCCRI), UT Health Science Center, San Antonio, TX, USA.ORCID 0000-0001-6639-7707
Concetta QuintarelliDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.
Janet ShipleySarcoma Molecular Pathology, Divisions of Molecular Pathology, The Institute of Cancer Research, London, UK.ORCID 0000-0001-6748-8678
Lucio MieleDepartment of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.ORCID 0000-0002-5853-7287
Javed KhanOncogenomics Section, Genetics Branch, National Cancer Institute, NIH,, Bethesda, MD, USA.ORCID 0000-0002-5858-0488
Peter J HoughtonGreehey Children's Cancer Research Institute (GCCRI), UT Health Science Center, San Antonio, TX, USA.
Francesco MaramponDepartment of Radiological Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.
Berkley E GryderDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0003-0130-2302
Biagio De AngelisDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.ORCID 0000-0002-7938-737X
Franco LocatelliDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.ORCID 0000-0002-7976-3654
Rossella RotaDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy. rossella.rota@opbg.net.ORCID 0000-0002-9408-7711
Bambino Gesù Children's Hospital · ITThe University of Texas Health Science Center at Houston · USNational Cancer Institute · USCase Western Reserve University · USCity Of Hope National Medical Center · USInstitute of Cancer Research · GBUniversity Children's Hospital Zurich · CHUniversity of Rome Tor Vergata · ITCold Spring Harbor Laboratory · USIcahn School of Medicine at Mount Sinai · USLouisiana State University Health Sciences Center New Orleans · USRoyal Marsden NHS Foundation Trust · GBSapienza University of Rome · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Birmingham · GB
Funding
Single-Cell Biology Shared ResourceP30CA045508 · NCI · COLD SPRING HARBOR LABORATORY · PI David A Tuveson · 1987 to 2026
$118.9MAssociazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) 5x mille 9962Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 10338Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 15312Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 24696Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 27794Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) MFGA 22889Ministero della Salute (Ministry of Health, Italy) 5x milleMinistero della Salute (Ministry of Health, Italy) Ricerca Finalizzata GR-2013-02359212Ministero della Salute (Ministry of Health, Italy) Ricerca Finalizzata GR-2016-02364546NCI NIH HHS P30 CA045508
Abstract
Rhabdomyosarcomas (RMS) are pediatric mesenchymal-derived malignancies encompassing PAX3/7-FOXO1 Fusion Positive (FP)-RMS, and Fusion Negative (FN)-RMS with frequent RAS pathway mutations. RMS express the master myogenic transcription factor MYOD that, whilst essential for survival, cannot support differentiation. Here we discover SKP2, an oncogenic E3-ubiquitin ligase, as a critical pro-tumorigenic driver in FN-RMS. We show that SKP2 is overexpressed in RMS through the binding of MYOD to an intronic enhancer. SKP2 in FN-RMS promotes cell cycle progression and prevents differentiation by directly targeting p27
Indexed as
RhabdomyosarcomaCarcinogenesisCell DifferentiationCell Line, TumorCell Transformation, NeoplasticCyclin-Dependent Kinase Inhibitor p57HumansMyoD ProteinS-Phase Kinase-Associated ProteinsTranscription FactorsCDKN1C protein, humanCyclin-Dependent Kinase Inhibitor p57MyoD1 myogenic differentiation proteinMyoD ProteinSKP2 protein, humanS-Phase Kinase-Associated ProteinsTranscription Factors
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.